The success of modern medicine is based on the ability to control infections. But decades of antibiotic overuse—in hospitals, communities, and farms—have fueled a global rise in resistant microbes. These “superbugs” thrive where antibiotics are used freely and poorly controlled, silently spreading to humans, animals and the environment. International monitoring has revealed stark differences between countries due to differing drug policies and health care systems. In developing regions, weak surveillance and over-the-counter sales of antibiotics have exacerbated the crisis. Because of these challenges, researchers have turned to an urgent question: how can the world curb antimicrobial resistance (AMR) before it overtakes modern medicine?
A research team from Jilin University and Peking Union Medical College Hospital published a comprehensive review (DOI: 10.12290/xhyxzz.2025-0704) in Medical Journal of Peking Union Medical College Hospital (September 2025). The study integrates global surveillance data and clinical insights to chart the spread of resistant bacteria and fungi. By revealing the molecular mechanisms and treatment challenges of AMR, it provides a scientific basis for global action and highlights how strategic use of antibiotics could slow the tide of resistance.
The authors examined data from international surveillance programs such as CARS, SENTRY and One Health Trust-ResistanceMap, revealing striking global variations. Escherichia coli and Klebsiella pneumoniae remain the most prevalent culprits, with β-lactamase-producing strains widespread in Asia and carbapenem-resistant variants increasing across Europe and the Americas. The infamous Acinetobacter baumannii and Pseudomonas aeruginosa are particularly difficult to treat, showing resistance levels of over 70% in some areas. In contrast, Northern Europe reports single-digit rates, reflecting effective management.
At the front of the fungi, Candida auris has emerged as a nearly pan-resistant pathogen, whereas Aspergillus fumigatus azole resistance is evolving, in part due to the use of agricultural fungicides. The review dissects the genetic pathways—such as β-lactamase expansion, carbapenemase evolution, and efflux pump overexpression—that underlie these threats. In response, the authors recommend individualized therapy guided by pharmacokinetic and pharmacodynamic data, including the use of β-lactamase inhibitors, tigecycline, and polymyxin-based combinations. Their message is clear: smart prescribing and global collaboration are as vital as new drugs to combat resistance.
AMR represents a slow pandemic. Our review shows that patterns of resistance are constantly changing, shaped by human behavior, health care systems, and environmental factors. No country can fight this battle alone. What is needed is a unified One Health strategy bridging medicine, agriculture and ecology. Only by strengthening surveillance, optimizing antibiotic use and driving innovation can we prevent a future where common infections become deadly again.”
Dr. Xuesong Xu, lead author of the study
The findings highlight a key truth: AMR is not just a medical issue – it is a global systems challenge. The authors call for coordinated international surveillance, stricter prescription controls and responsible use of antibiotics in agriculture. Hospitals must adopt AI-assisted genomic diagnosis and decision-making systems to adjust treatments in real time. Investment in new generation antimicrobials and β-lactamase inhibitors is equally urgent. Beyond drugs, education and policy reform are key to maintaining the effectiveness of existing treatments. If global collaboration succeeds, the tide of resistance may yet be turned—ensuring the foundations of modern medicine for generations to come.
Source:
Journal Reference:
